Lumateperone for Bipolar Depression
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the effectiveness of lumateperone in treating mood symptoms in individuals with bipolar disorder. The study will also examine inflammation and use MRI scans to analyze the brain's biological age. It targets individuals with bipolar type I depression for at least four weeks and a body mass index (BMI) over 30. Participants should not have other severe psychiatric illnesses or be using certain medications. As a Phase 4 trial, this research aims to understand how this FDA-approved and effective treatment benefits a broader range of patients.
What is the safety track record for lumateperone?
Research has shown that lumateperone is generally safe and well-tolerated for treating depression in people with bipolar disorder. Previous studies have found no new safety concerns. Participants reported a low risk of side effects, such as movement problems or changes in metabolism.
For those with bipolar I disorder, lumateperone demonstrated a safety profile similar to a placebo, indicating it did not cause more side effects than an inactive pill. Additionally, long-term studies have confirmed that lumateperone remains safe over time when used with other antidepressants.
The FDA has approved lumateperone for treating bipolar depression, further supporting its safety based on earlier findings. This approval indicates it is considered safe for treating this condition.12345Why are researchers enthusiastic about this study treatment?
Lumateperone is unique because it targets bipolar depression with a different mechanism of action compared to traditional treatments like lithium or valproate. While most medications for bipolar depression work by stabilizing mood through broad effects on neurotransmitters like serotonin, lumateperone specifically modulates glutamate and serotonin pathways in the brain. This targeted action may lead to fewer side effects and a quicker onset of relief for patients. Researchers are excited about lumateperone as it could offer a more precise and potentially more effective treatment option for those struggling with bipolar depression.
What is the effectiveness track record for lumateperone in treating bipolar depression?
Research has shown that lumateperone can greatly improve depression symptoms in people with bipolar disorder. Studies have found that taking 42 mg of lumateperone noticeably reduces these symptoms. In one study, 51% of participants experienced a positive change, and 39% saw their symptoms completely disappear. This treatment is effective for both bipolar I and bipolar II disorder. These findings support using lumateperone as an effective way to manage bipolar depression.13467
Who Is on the Research Team?
Michael E Henry, MD
Principal Investigator
Massachusetts General Hospital
Are You a Good Fit for This Trial?
This trial is for adults with bipolar disorder and depression who are also overweight or obese. Participants should be able to take MRI scans and must not have conditions that would make it unsafe to use lumateperone or participate in the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive lumateperone treatment for Bipolar type I depression
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Lumateperone
Trial Overview
The study tests how a medication called lumateperone (42 mg) affects mood, inflammation, obesity, and brain aging in people with bipolar depression over about 6 weeks. Brain scans will be done at the start of the trial.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Lumateperone treatment for Bipolar type I depression
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor
Johnson and Johnson Medical
Collaborator
Johnson & Johnson K.K. Medical Company
Industry Sponsor
Citations
NCT06372964 | Multicenter Study of Lumateperone for the ...
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) ...
Lumateperone monotherapy for major depressive episodes ...
Additionally, in a recent study, lumateperone 42 mg monotherapy significantly improved depression in patients with bipolar I or bipolar II ...
The efficacy of lumateperone on symptoms of depression ...
Lumateperone 42 mg treatment significantly improved depression symptoms compared with placebo, with consistent efficacy across a broad range of symptoms in ...
Primary Efficacy - Bipolar Depression - Caplyta HCP
Explore the data on the efficacy of CAPLYTA in adults with bipolar depression. Please see full Prescribing Information, including Boxed WARNINGS.
Efficacy and Safety of Lumateperone for Major Depressive ...
In summary, 42 mg/day of lumateperone significantly improved depression in patients with bipolar I or bipolar II disorder experiencing an acute ...
NCT04285515 | Clinical Trial Evaluating Lumateperone ...
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of lumateperone monotherapy
Long-Term Safety Data | CAPLYTA® (lumateperone)
View the long-term data from an open-label safety trial of CAPLYTA as an adjunctive therapy for major depressive disorder (MDD) in adults.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.